Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study

M.G. Bousser,Pierre Amarenco,Ángel Chamorro,M. Fisher,Ian Ford,Keith A.A. Fox,M G Hennerici,Heinrich Mattle,Peter M. Rothwell

Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study

2009

M.G. Bousser
Pierre Amarenco
Ángel Chamorro
M. Fisher
Ian Ford
Keith A.A. Fox
M G Hennerici
Heinrich Mattle
Peter M. Rothwell

Background: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagon

Keywords:

Relative risk reduction
Cardiology
Internal medicine
Platelet aggregation inhibitor
Diabetes mellitus
Dementia
Myocardial infarction
Terutroban
Stroke
Aspirin
Medicine
Antithrombotic

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations